Navigation Links
Cordex Pharma Presents 'New Frontiers in Cardiovascular Medicines' on January 29
Date:1/23/2009

forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements. The forward-looking statements are based on current expectations, estimates and projections made by management. Cordex intends for the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," or variations of such words are intended to identify such forward-looking statements. All statements in this release regarding the future outlook related to Cordex are forward-looking statements, including, but not limited to, the statements regarding ATPace's expected entry into a pivotal Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia and the anticipated results of the trial, CDP-1050's expected commencement of a Phase 2 safety clinical trial in heart failure patients. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Such risks include the risk that the clinical trial for approval of ATPace and the Phase 2 clinical trial for our CDP-1050 investigational drug may not be successful, that our preclinical program to develop new chemical entities that target a newly discovered pathway in the pathophysiology of chronic obstructive pulmonary disease may not be successful, and that our technology may not lead to expected results including the development or the successful commercialization of technologies relating to the use of ATP or nitric oxide. Additional uncertainties and risks are described in Cordex's most recently filed SEC documents, such as its most recent annual report on Form
'/>"/>
SOURCE Cordex Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Axikin Pharmaceuticals Spins out of Actimis
2. Asbestos, Pharmaceutical Liability, Construction Defects, Nanotech: Covered by Targeted CLE Teleconferences
3. FDA Issues Complete Response Letter to SCOLR Pharmas Abbreviated New Drug Application for CDT(R) 12-Hour Pseudoephedrine
4. BioMed Realty Trust Extends Leases With Vertex Pharmaceuticals Through 2015
5. Cracking the Code: Exclusive Conference to Reveal Secrets of Chinese Pharmaceutical Industry
6. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
7. Cumberland Pharmaceuticals Appoints Lee Product Director
8. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
9. ERYtech Pharma Signs an Agreement With the Penn Jersey Region of American Red Cross
10. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
11. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... Calif. , April 20, 2015   Meditope ... products using its proprietary technology, today announced presentation of ... for the development of antibody-drug conjugates (ADCs). The data were ... 2015, taking place April 18-22 in Philadelphia ... about these data which point to the many commercial ...
(Date:4/17/2015)... , April 17, 2015  Centrillion ... a SBIR grant from the National Human ... Institutes of Health (NIH). The grant will ... in the development of breakthrough genomic technologies, ... specially fabricated substrates. Centrillion has been developing ...
(Date:4/17/2015)... , April 17, 2015  Guggenheim Securities, the investment ... announced the hiring of William Tanner as ... Mr. Tanner will start work at Guggenheim in ... office. "Bill brings a wealth ... to our experienced and highly acclaimed healthcare team," said ...
(Date:4/17/2015)... BellBrook Labs announced today that ... the powerful Orthogonal Pooled Screening (OPS) Platform developed ... the Lankenau Institute for Medical Research (LCGC) in ... improve successful drug discovery outcomes using far more ... libraries available nowhere else, coupled to a state-of-the-art ...
Breaking Biology Technology:Meditope Biosciences Presents Data At The American Association Of Cancer Research (AACR) Annual Meeting Validating Its SnAP Technology Platform 2Guggenheim Securities Hires Biotech Analyst William Tanner in Expansion of Healthcare Coverage 2BellBrook Labs and Lankenau Institute Partner to Accelerate Drug Discovery using Orthogonal Pooled Screening 2
... 7, 2008 MaxCyte, Inc., a,clinical-stage therapeutics ... loading systems, announces that Anthony Recupero, Ph.D.,Vice ... on Tuesday,April 8, 2008, at 2:00PM at ... Dr. Recupero,s presentation will discuss the development ...
... Excellence and Patient Ease-of-Use, BROOKFIELD, Wis., April ... won the 2008 Medical Design Excellence Awards (MDEA) ... Genesis DM won in the,rehabilitation and assistive-technology products ... monitoring device is,ideal for both the patient and ...
... Boston,Scientific Corporation (NYSE: BSX ) will webcast ... ended March 31, 2008 on,Tuesday, April 22, at 8:30 ... Jim Tobin, President and Chief Executive,Officer, Paul LaViolette, Chief ... Financial Officer., The live webcast and archived replay ...
Cached Biology Technology:Honeywell HomMed Wins 2008 Medical Design Excellence Award for Genesis DM Remote Care Device 2Honeywell HomMed Wins 2008 Medical Design Excellence Award for Genesis DM Remote Care Device 3Boston Scientific to Webcast Conference Call Discussing First Quarter Financial Results 2
(Date:4/10/2015)... , April 10, 2015 Research ... of the "Security Competitive Profiles - NEC" ... , NEC will continue to supply a ... the market, with a company focus on the development ... Winning opportunities in the Asia-Pacific ...
(Date:4/6/2015)... Apr. 6, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... patent 62/143028 for MINIATURE, MULTI-PURPOSE ANTENNA ... NXT-ID introduces a new revolutionary method ... surrounds the use of miniature antenna modules for ...
(Date:4/2/2015)... , April 2, 2015 According ... 2015 attributed to somewhat higher than 125 MSEK. This ... year-end report 2014 that revenues for Q1 2015 would ... company reported for Q4 2014. The operating result for ... negative. The complete interim report will as previously communicated ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Revises Revenues for Q1 2015 2
... In 2005, 40.3 million people in the world, including 25.8 ... of the origin of HIV-1, responsible for the AIDS pandemic, ... Some months ago, the team of Martine Peeters, director of ... research unit UMR 145 jointly involving the IRD and the ...
... among other roles. For the first time, scientists using ... of its kind in the Americas) have seen how ... the first aid/repair after DNA injuries to the region ... lie out of the visual reach of scientists. The benefits ...
... University researchers have shown that some simple biodegradable liquids ... development that could significantly impact medicine. , When the ... to open wounds, the peptides self-assemble into a nanoscale ... bleeding. Once the injury heals, the nontoxic gel is ...
Cached Biology News:Wild gorillas carriers of a SIV virus close to the AIDS virus 2Nanoscale microscope sheds first light on gene repair 2MIT material stops bleeding in seconds 2MIT material stops bleeding in seconds 3
...
... Pierce scientists developed the Easy-Titer Human IgM ... a simple, sensitive, and easy-to-perform assay for ... an ELISA. This kit incorporates a simple ... of IgM concentration from 15-500 ng/ml in ...
... Stabilizer is an aqueous solution that contains ... stabilizing chemicals in a saline solution, pH ... of 0.02% methylisothiazolone and 0.02% bromonitrodioxane as ... a diluent and stabilizer for biologically active ...
... reagent; Ideal for clarifying many items ... nucleic acids, & proteoglycans; Contains no ... downstream processing; Utilizes a reagent that ... as a suspension in saline; Simple ...
Biology Products: